Osaka Metropolitan University researchers report a novel method for producing high-quality canine mesenchymal stem cells derived from induced pluripotent stem cells sourced from various somatic tissues. This approach addresses limitations in MSC proliferation and standardization that previously constrained veterinary regenerative therapies. Among tested cell origins, urine-derived iPSCs yielded robust MSC populations. The findings offer a scalable and consistent platform for developing advanced treatments in veterinary medicine and translational research models.